News

FB102 is a first‑in‑class anti‑CD122 antibody that has shown statistically significant benefit in a Phase 1b vitiligo trial and produced positive results in a Phase 1b celiac study last year. Phase 2 data for celiac disease are anticipated in the second half of 2024, and the program is also being evaluated for alopecia areata and other autoimmune c...

Full article

Forte Biosciences announced that it will be acquired by Belgian‑Dutch immunology firm argenx for $77 per share in a fully cash‑priced, all‑cash transaction valued at approximately $2.2 billion. The offer represents a premium of roughly 40 % to Forte’s previous closing price and about 86 % to its volume‑weighted average price as of July 9, following...

Full article

The acquisition is expected to complete in Q3 2026, after which Forte’s shares will be converted to cash at the $77 per share price. The deal is seen as a strategic fit for argenx, aligning with its playbook of compelling biology, strong clinical validation, and broad potential to address unmet patient needs.

Full article

Bank of Marin Bancorp (BMRC) shares were up more than 6% in Monday trading following its Q2 results. Earlier, the company posted quarterly earnings of $0.58 per diluted share, swinging from a loss of $0.53 a year earlier. Analysts polled by FactSet expected $0.52. Revenue for the quarter ended June 30, expressed as the sum of net interest income an...

Full article

Bank of Marin Bancorp (NASDAQ:BMRC) reported strong second‑quarter earnings, with net income rising to $9.2 million or $0.58 per share, compared to $8.5 million or $0.53 per share in the previous quarter. The company's tax‑equivalent net interest margin expanded 14 basis points to 3.38%, driven by higher loan yields and lower deposit costs. Loan pr...

Full article

The current P/E ratio of 27.4x is above the European Energy Services average of 13.5x and a fair ratio of 24.6x, which may impact sentiment if growth underwhelms. Investors are advised to review Saipem's data themselves and assess the balance of risks and rewards before making any moves. The company's valuation breakdown provides further analysis o...

Full article

The company's technical capabilities and capital‑light bidding for €53 billion in new tenders are setting the stage for a multi‑year uplift in both order intake and structurally higher EBITDA margins. However, concerns about Saipem's heavy reliance on conventional oil and gas projects and potential project delays or cancellations could challenge th...

Full article

Saipem's (SPM) recent performance has investors weighing its €4.41 last close against returns across the week, month, and past 3 months. The stock's strong momentum over a longer period is evident, with a 1-year total shareholder return of 98.31% and year-to-date share price return of 76.32%. This points to potential undervaluation, with most popul...

Full article

NOS’s net financial debt increased to EUR1 078 million primarily due to dividend payments. The company expects future CapEx to decline, but no specific guidance was provided for operating costs. Despite a weaker B2B quarter, NOS does not expect negative EBITDA growth in the second half.

Full article

NOS’s sustainability performance was recognized globally, being classified as one of the world’s most sustainable companies by TIME. The company’s AI‑driven efficiencies and disciplined cost management supported EBITDA growth. However, consolidated revenues were impacted by declines in B2C and wholesale segments, with B2C segment revenues declining...

Full article